viewTRACON Pharmaceuticals

TRACON Pharmaceuticals ends 1Q with $30.4M to fund its cancer drug trials

The company said it had enough money as of March 31 to fund its operations into the second half of 2022

TRACON Pharmaceuticals -
TRACON remains on track to deliver interim data for its pivotal ENVASARC trial by the second half of this year

TRACON Pharmaceuticals Inc (NASDAQ:TCON) ended the first quarter of 2021 on March 31 with cash and equivalents of $30.4 million, which it said will fund its operations into the second half of 2022.

The company also noted that as of May 5, it has initiated 22 US clinical sites and enrolled more than 20 patients in the pivotal ENVASARC trial of single-agent envafolimab and envafolimab combined with Yervoy, which has triggered the initial Data Monitoring Committee review of safety data from each cohort.

“We continue to be pleased with the pace of enrollment in the pivotal ENVASARC trial and remain on track to deliver interim data in the second half of this year and final data in 2022, CEO Dr Charles Theuer said in a statement.

READ: TRACON Pharmaceuticals driving the development of targeted therapies for cancer via collaborations

“We have now initiated 22 sites and have enrolled more than 20 patients which has triggered the initial Data Monitoring Committee review of safety data from each cohort, which we expect later this quarter,” Dr Theuer added.

In April, TRACON resubmitted its Orphan Drug Designation application to the US Food and Drug Administration (FDA) in response to a request for preclinical or clinical evidence of activity for its clinical-stage drug envafolimab for treating sarcoma. It expects correspondence from the FDA this quarter based on the amended application.

The company also outlined some other key upcoming milestones, including:

  • Orphan Drug Designation for envafolimab in soft tissue sarcoma from the FDA in 1H 2021
  • Independent Data Monitoring Committee review of ENVASARC safety data in 1H 2021
  • American Society of Clinical Oncology (ASCO) presentation of ENVASARC pivotal trial design in 1H 2021
  • ASCO presentation of TJ004309 Phase 1 data in 1H 2021
  • Interim ENVASARC efficacy and safety data in 2H 2021
  • Request FDA breakthrough therapy designation or Fast Track designation for envafolimab in 2H 2021
  • Decision on the envafolimab New Drug Application (NDA) in MSI-H/dMMR cancer that is under priority review by the Chinese National Medical Products Administration (NMPA)

TRACON has positioned itself as a collaboration partner that leads the regulatory filings, clinical trials, as well as US commercialization of best-in-class drug candidates, as an alternative to expensive contract research organization (CRO) based development.

Contact Sean at sean@proactiveinvestors.com

Quick facts: TRACON Pharmaceuticals


Price: 4.34 USD

Market Cap: $84.33 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


TRACON's ENVASARC trial to continue after 2nd Independent Data Monitoring...

TRACON Pharmaceuticals (NASDAQ:TCON) Inc (NASDAQ:TCON) CEO Charles Theuer spoke to Proactive about the latest advancements on its ENVASARC trial to treat cancer with its therapy called envafolimab. Theuer says that the Independent Data Monitoring Committee has recommended that the trial...

on 08/10/2021

2 min read